SEC Comment Letter for Applied Molecular Transport Inc. (CIK 0001801777) — Mar 24, 2021
Applied Molecular Transport Inc. (CIK 0001801777)
Date: March 24, 2021 · CIK: 0001801777 · Accession: 0000000000-21-003576
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo March 24, 2021 Tahir Mahmood, Ph.D. Chief Executive Officer Applied Molecular Transport Inc. 1 Tower Place, Suite 850 South San Francisco, California 94080 Re:Applied Molecular Transport Inc. Draft Registration Statement on Form S-1 Submitted March 19, 2021 CIK No. 0001801777 Dear Dr. Mahmood: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael Coke
Show Raw Text
United States securities and exchange commission logo
March 24, 2021
Tahir Mahmood, Ph.D.
Chief Executive Officer
Applied Molecular Transport Inc.
1 Tower Place, Suite 850
South San Francisco, California 94080
Re:Applied Molecular Transport Inc.
Draft Registration Statement on Form S-1
Submitted March 19, 2021
CIK No. 0001801777
Dear Dr. Mahmood:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael Coke